Oppenheimer raised the firm’s price target on CymaBay to $26 from $22 and keeps an Outperform rating on the shares. Following the NDA submission of seladelpar for 2L treatment of PBC, the firm looks forward to a potential mid-February acceptance with PDUFA in mid-August assuming priority review. Oppenheimer met with management to discuss key priorities for 2024 and came away encouraged by the potential impact of seladelpar on evolving PBC treatment dynamics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- CymaBay Therapeutics Boosts Director Equity, Announces Officer Changes
- Guggenheim ups CymaBay price target to $28, sees M&A potential
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CymaBay: Analysis of Phase 3 ENHANCE study published in Hepatology
- The biotech stocks to own in 2024, according to Piper Sandler